Melissa Hudson

Director Cancer Survivorship Division in the Department of Oncology and Co-Leader Cancer Control & Survivorship Program St. Jude USA

Melissa M. Hudson, MD, is currently a Member and Director of the Cancer Survivorship Division in the Department of Oncology and holds the Charles E. Williams Endowed Chair of Oncology-Cancer Survivorship. She directs the St. Jude After Completion of Therapy (ACT) Program, which now monitors over 6000 long-term childhood cancer survivors treated on St. Jude trials.

Dr. Hudson disseminated the St. Jude model of risk-based survivor care in her role as Co-Chair of the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer and Co-Chair of the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG). She is also the Chair of the Education Committee of the Childhood Cancer Survivor Study (CCSS) and a member of the CCSS Executive Committee.

She works collaboratively with multidisciplinary investigators at St. Jude and within COG, IGHG and the CCSS in research initiatives evaluating biomedical and psychosocial outcomes among childhood cancer survivors and translating data from health outcomes research into evidence-informed clinical practice guidelines and interventions to improve the quality and duration of survival after childhood cancer.

She has published widely on her research initiatives in pediatric Hodgkin lymphoma, late treatment sequelae after childhood cancer, and health surveillance of childhood cancer survivors.

Jacqueline Loonen

Pediatric oncologist and head of the Radboudumc Center of Expertise Cancer Survivorship.

Institute

Radboud University Medical Center, Nijmegen, The Netherlands
Department of Hematology

Expertise

My main interest and expertise is cancer survivorship care (CSC). In the Radboudumc Center of Expertise Cancer Survivorship I implemented an innovative care model for CSC: the “Personalized Cancer Survivorship Care model”, which comprises a multidisciplinary care infrastructure based on (international) guidelines and Person Centred Care.

I am a member of the core group of the Dutch Childhood Cancer Survivor Study LATER (DCCSS LATER) and project leader of the DCCSS LATER studies on: Cancer related fatigue, male fertility, benign skin disorders, and hypofunction of the spleen. As a consortium member of the PanCareFollowUp project I am work-package leader of the work-package on life style intervention and Person Centred Care.

Michael von Wolff

Michael von Wolff is Head of the Division of Gynaecological Endocrinology and Reproductive Medicine at the Women's University Hospital, Berne, Switzerland.

Regarding fertility preservation he has established the German speaking network of fertility preservation before cytotoxic therapies “FertiPROTEKT” (www.fertiprotekt.com) in 2006. Furthermore he had founded the ESHRE Task Force on fertility preservation, has co-founded the ESHRE SIG “Fertility preservation” and is Vice president of the ISFP since 2021. He is also President of the Swiss society of Reproductive Medicine since 2019. 

In fertility preservation he focuses on ovarian stimulation and ovarian tissue transplantation. To provide physicians with practical guidelines to indicate and perform fertility preservation he has published the book “Fertility preservation on oncological and non-oncological diseases – a practical guide”, Springer, 2020.